0001193125-23-194657.txt : 20230726 0001193125-23-194657.hdr.sgml : 20230726 20230726163801 ACCESSION NUMBER: 0001193125-23-194657 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20230720 ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230726 DATE AS OF CHANGE: 20230726 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOLASE, INC CENTRAL INDEX KEY: 0000811240 STANDARD INDUSTRIAL CLASSIFICATION: DENTAL EQUIPMENT & SUPPLIES [3843] IRS NUMBER: 870442441 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36385 FILM NUMBER: 231114105 BUSINESS ADDRESS: STREET 1: 27042 TOWNE CENTRE DRIVE STREET 2: SUITE 270 CITY: FOOTHILL RANCH STATE: CA ZIP: 92610 BUSINESS PHONE: 949-361-1200 MAIL ADDRESS: STREET 1: 27042 TOWNE CENTRE DRIVE STREET 2: SUITE 270 CITY: FOOTHILL RANCH STATE: CA ZIP: 92610 FORMER COMPANY: FORMER CONFORMED NAME: BIOLASE TECHNOLOGY INC DATE OF NAME CHANGE: 19941117 FORMER COMPANY: FORMER CONFORMED NAME: LASER MEDICAL TECHNOLOGY INC DATE OF NAME CHANGE: 19941117 FORMER COMPANY: FORMER CONFORMED NAME: LASER ENDO TECHNIC CORP DATE OF NAME CHANGE: 19920708 8-K 1 d540125d8k.htm 8-K 8-K
BIOLASE, INC false 0000811240 --12-31 0000811240 2023-07-20 2023-07-20

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): July 20, 2023

 

 

BIOLASE, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-36385   87-0442441
(State or other jurisdiction
of incorporation)		   (Commission File No.)   (IRS Employer
Identification No.)

27042 Towne Centre Drive, Suite 270

Lake Forest, California 92610

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (949) 361-1200

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange on
which registered

Common Stock, par value $0.001 per share   BIOL  

The Nasdaq Stock Market LLC

(Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 3.03.

Material Modification to Rights of Security Holders.

To the extent required by Item 3.03 of Form 8-K, the information regarding the Reverse Stock Split (as defined below) contained in Item 5.03 of this Current Report on Form 8-K is incorporated by reference in this Item 3.03.

 

Item 5.03.

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On July 20, 2023, the stockholders of BIOLASE, Inc., a Delaware corporation (the “Company”), approved a proposal at the Company’s special meeting of stockholders (the “Special Meeting”) further amending the Company’s Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), to effect a reverse stock split of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a ratio between one-for-two (1:2) and one-for-one hundred (1:100), without reducing the authorized number of shares of Common Stock. Following the Special Meeting, the Company’s Board of Directors approved a final split ratio of one-for-one hundred (1:100). Following such approval, on July 26, 2023, the Company filed an amendment to the Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to effect the reverse stock split, with an effective time of 11:59 p.m. Eastern Time on July 27, 2023 (the “Reverse Stock Split”).

No fractional shares will be issued in connection with the Reverse Stock Split. In lieu of fractional shares, Computershare Trust Company, N.A., as exchange agent (“Computershare”), will aggregate all fractional shares and arrange for them to be sold in a timely manner at the then-prevailing prices on the Nasdaq Capital Market. After completing such sale, Computershare will pay to each stockholder of record such stockholder’s pro rata share of the net proceeds derived from the sale of the fractional interest to which such stockholder would otherwise be entitled.

The 1-for-100 Reverse Stock Split will reduce the number of outstanding shares of Common Stock from approximately 104 million shares to approximately 1.04 million shares. Proportional adjustments will be made to the number of Common Stock issuable upon exercise or conversion of the Company’s outstanding equity awards and warrants, as well as the applicable exercise price.

After the Reverse Stock Split, the trading symbol for the Common Stock will continue to be “BIOL.” The new CUSIP number for the Common Stock following the Reverse Stock Split is 090911702.

The description of the Amendment set forth above does not purport to be complete and is qualified in its entirety by the full text of the Amendment, a copy of which is attached hereto as Exhibit 3.1 and is incorporated herein by reference.

 

Item 5.07.

Submission of Matters to a Vote of Security Holders.

The following are the results of the voting on the proposals submitted to stockholders at the Company’s Special Meeting of Stockholders held on July 20, 2023.

Proposal 1 – Stockholders voted to approve the adoption of the Amendment to the Certificate of Incorporation to effect a reverse stock split of Company Common Stock (without reducing the authorized number of shares of Company Common Stock), if and when determined by the Company’s Board of Directors:

 

For   Against   Abstain   Broker Non-Votes
20,889,544,676   14,072,832,774   363,902,539   —

Proposal 2 – To approve an adjournment of the Special Meeting, to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event there are not sufficient votes in favor of the Amendment to the Company’s Certificate of Incorporation to effect a reverse stock split:

The Company’s stockholders approved Proposal 1. The votes cast were as follows:

 

For   Against   Abstain   Broker Non-Votes
23,071,478,430   11,853,155,314   401,646,245   —

The Board of Directors has determined not to adjourn the Special Meeting to solicit additional proxies.

 

-2-

Item 8.01.

Other Events.

The primary purpose of the 1-for-100 Reverse Stock Split is to raise the per-share trading price of the Common Stock to allow for its continuous listing on the Nasdaq Capital Market, among other benefits. The Nasdaq Capital Market requires, among other things, that a listing a company’s common stock maintain a minimum bid price of at least $1.00 per share. However, there can be no assurance that the Reverse Stock Split will have the desired effect of sufficiently raising the bid price of the Common Stock for the required period.

In addition, on July 26, 2023, the Company issued a press release relating to the Reverse Stock Split described in this Current Report on Form 8-K. A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference.

 

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit
No.		   

Description of Exhibits

  3.1    Seventh Amendment to Restated Certificate of Incorporation of BIOLASE, Inc.
99.1    Press release of BIOLASE, Inc., dated July 26, 2023
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

-3-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    BIOLASE, INC.
Date: July 26, 2023     By:  

/s/ John R. Beaver

    Name:   John R. Beaver
    Title:   Chief Executive Officer

 

-4-

EX-3.1 2 d540125dex31.htm EX-3.1 EX-3.1

Exhibit 3.1

SEVENTH AMENDMENT

TO

RESTATED CERTIFICATE OF INCORPORATION

OF

BIOLASE, INC.

BIOLASE, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, hereby certifies as follows:

 

1.

This Certificate of Amendment amends the provisions of the Corporation’s Restated Certificate of Incorporation, as amended and filed with the Secretary of State of the State of Delaware (the “Restated Certificate of Incorporation”).

 

2.

Article III of the Restated Certificate of Incorporation is hereby amended and restated in its entirety as follows:

THIRD. The total number of shares of stock that the Corporation shall have the authority to issue is ONE HUNDRED EIGHTY ONE MILLION (181,000,000) shares of which stock ONE HUNDRED EIGHTY MILLION (180,000,000) shares of $0.001 par value per share shall be common stock and of which ONE MILLION (1,000,000) shares of $0.001 par value per share shall be preferred stock.

Upon the filing and effectiveness (the “Effective Time”) pursuant to the General Corporation Law of the State of Delaware of this Seventh Amendment to Restated Certificate of Incorporation of the Corporation, each ONE HUNDRED (100) shares of common stock either issued and outstanding or held by the Corporation in treasury stock immediately prior to the Effective Time shall, automatically and without any action on the part of the respective holders thereof, be combined and converted into one (1) share of common stock (the “Reverse Stock Split”).

No fractional shares shall be issued in connection with the Reverse Stock Split. In lieu thereof, the aggregate of all fractional shares otherwise issuable to the holders of record of common stock shall be issued to the transfer agent, as agent for the accounts of all holders of record of common stock and otherwise entitled to have a fraction of a share issued to them. The sale of all of the fractional interests will be effected by the transfer agent as soon as practicable after the Effective Time on the basis of the prevailing market prices of the common stock at the time of the sale. After such sale, the transfer agent will pay to such holders of record their pro rata share of the total net proceeds derived from the sale of the fractional interests.

 

3.

The foregoing amendment was duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware.

 

4.

All other provisions of the Restated Certificate of Incorporation shall remain in full force and effect.

 

5.

The foregoing amendment shall be effective as of 11:59 p.m., Eastern Time, on the date of filing with the Secretary of State of the State of Delaware.

*****

 

 

 

LOGO

 

 

-1-

IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be signed this 26th day of July, 2023.

 

BIOLASE, INC.
By:  

/s/ John R. Beaver

 

Name: John R. Beaver

Title: Chief Executive Officer

 

-2-

EX-99.1 3 d540125dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

BIOLASE ANNOUNCES 1-FOR-100 REVERSE STOCK SPLIT

COMMON STOCK WILL BEGIN TRADING ON SPLIT-ADJUSTED BASIS ON JULY 28, 2023

Lake Forest, Calif., July 26, 2023 – BIOLASE, Inc. (NASDAQ: BIOL) (“BIOLASE” or the “Company”), a global leader in dental lasers, today announced that it held a special meeting of its stockholders on July 20, 2023 where the Company’s stockholders granted the Board of Directors the discretion to effect a reverse stock split of the Company’s common stock at a ratio between 1-to-2 and 1-to-100. Shortly following the special meeting, the Board of Directors exercised such discretion to effect a 1-for-100 reverse stock split that will become effective at 11:59 p.m. Eastern Time on July 27, 2023, and the Company’s common stock will begin trading on a split-adjusted basis at the opening of the market on July 28, 2023.

The 1-for-100 reverse stock split will reduce the number of outstanding shares of Company common stock from approximately 104 million shares to approximately 1.04 million shares. Proportional adjustments will be made to the number of shares of BIOLASE’s common stock issuable upon exercise or conversion of BIOLASE’s outstanding equity awards and warrants, as well as the applicable exercise price. There will be no change to the total number of authorized shares of Company common stock as set forth in the Restated Certificate of Incorporation of the Company, as amended.

The primary purpose of the 1-for-100 reverse stock split is to raise the per-share trading price of the Company’s common stock to allow for its continuous listing on the Nasdaq Capital Market, among other benefits. The Nasdaq Capital Market requires, among other things, that a listing a company’s common stock maintain a minimum bid price of at least $1.00 per share.

Information for BIOLASE Stockholders

At the effective time of the reverse stock split, BIOLASE stockholders will receive one new share of Company common stock for every 100 shares held. Record holders of Company common stock will receive a transaction statement with respect to the exchange of such shares for post-reverse split shares. Computershare Trust Company, N.A., the transfer agent for Company common stock, will act as the exchange agent, and can be contacted at (800) 546-5141.

BIOLASE will not issue fractional shares that result from the reverse stock split. Rather, Computershare will aggregate all fractional shares and arrange for them to be sold in a timely manner after the effective time of the reverse stock split at the then prevailing prices on the Nasdaq Capital Market. After such sale, Computershare will pay to each holder of record such stockholder’s pro rata share of the net proceeds derived from the sale of the fractional interest to which such holder would otherwise be entitled.

For more information on the reverse stock split, please refer to BIOLASE’s proxy materials for the July 20, 2023 special meeting of stockholders, which can be accessed through the investor portion of BIOLASE’s website at http://www.biolase.com and on the SECs EDGAR website, www.sec.gov.

 

1

About BIOLASE

BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE’s products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE’s proprietary laser products incorporate approximately 266 patented and 25 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE’s innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE’s principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. From 1998 through December 31, 2022, BIOLASE has sold over 45,500 laser systems to date in over 80 countries around the world. Laser products under development address BIOLASE’s core dental market and other adjacent medical and consumer applications.

For updates and information on Waterlase iPlus®, Waterlase Express™, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.

BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties. Forward-looking statements can be identified through the use of words such as may,” “might,” “will,” “intend,” “should,” “could,” “can,” “would,” “continue,” “expect,” “believe,” “anticipate,” “estimate,” “predict,” “outlook,” “potential,” “plan,” “seek,” and similar expressions and variations or the negatives of these terms or other comparable terminology. These statements are based upon current beliefs, expectations and assumptions and include statements regarding BIOLASE’s ability to realize any anticipated benefits from the reverse stock split, including maintaining its listing on the Nasdaq Capital Market. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE’s current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE’s current expectations depending upon a number of factors. These factors include, among others, those risks and uncertainties that are described in the “Risk Factors” section of BIOLASE’s annual report filed on Form 10-K filed with the Securities and Exchange Commission. Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements.

For further information, please contact:

EVC Group LLC

Michael Polyviou / Todd Kehrli

(732) 933-2754

mpolyviou@evcgroup.com / tkehrli@evcgroup.com

 

2

EX-101.SCH 4 biol-20230720.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 biol-20230720_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 6 biol-20230720_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 g540125g0726200931378.jpg GRAPHIC begin 644 g540125g0726200931378.jpg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g540125img1.jpg GRAPHIC begin 644 g540125img1.jpg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end XML 9 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Document and Entity Information
Jul. 20, 2023
Cover [Abstract]  
Entity Registrant Name BIOLASE, INC
Amendment Flag false
Entity Central Index Key 0000811240
Current Fiscal Year End Date --12-31
Document Type 8-K
Document Period End Date Jul. 20, 2023
Entity Incorporation State Country Code DE
Entity File Number 001-36385
Entity Tax Identification Number 87-0442441
Entity Address, Address Line One 27042 Towne Centre Drive
Entity Address, Address Line Two Suite 270
Entity Address, City or Town Lake Forest
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92610
City Area Code (949)
Local Phone Number 361-1200
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol BIOL
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 10 d540125d8k_htm.xml IDEA: XBRL DOCUMENT 0000811240 2023-07-20 2023-07-20 BIOLASE, INC false 0000811240 --12-31 8-K 2023-07-20 DE 001-36385 87-0442441 27042 Towne Centre Drive Suite 270 Lake Forest CA 92610 (949) 361-1200 false false false false Common Stock, par value $0.001 per share BIOL NASDAQ false EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( ,"$^E8'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " # A/I6U]#4_.\ K @ $0 &1O8U!R;W!S+V-O&ULS9)1 M2\,P$,>_BN2]O33%#4.7%\4G!<&!XEM(;EM8TX3DI-VWMZU;A^@'\#%W__SN M=W"-B=*$A"\I1$SD,-\,ONVR-''##D11 F1S0*]S.2:ZL;D+R6L:GVD/49NC MWB,(SE?@D;35I&$"%G$A,M58(TU"32&=\=8L^/B9VAEF#6"+'CO*4)45,#5- MC*>A;> *F&"$R>?O MJ%.%?_Q,X=8.?DD-V2ZON^[.LY-^Y0P?OST^N\;N&Z M3+HS./[*3M(IXH9=)K_5]P_;1Z8$%W7!UX58;067]5K>WGU,KC_\KL(^6+=S M_]CX(J@:^'47Z@M02P,$% @ P(3Z5IE&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" # A/I6;&AT^WX$ #+$0 & 'AL+W=O;"_I;/-)SYE4HL4Y$9J3*BQ6KHC>GU#>NY M!N4=OTNQ-0?'Q'5EJ=2+.YG&0R]P1"(1D742'+Y>Q40DB5,"CG_VHE[U3-?P M\/A#_;[L/'1FR8V8J.2+C.UFZ/4]$HL5+Q+[K+8_BWV'+IQ>I!)3_B?;W;UA MX)&H,%:E^\9 D,IL]\W?]H$X;$"/-&#[!JSDWCVHI+SEEH\&6FV)=G>#FCLH MNUJV!CB9N5&96PU7);2SHUL5%1!D2W@6D[O,2OM.IMENM"%J ]_"0]RM?K07 MO-D)LB."OQ3).6'!&7Q8][_-?6"K %D%R$J][A&]B7H5FOPU7AJK80C_;B+: M*83-"BZOKTW.(S'T('&-T*_"&WWW#>T%/R)\W8JOBZF/]C%[%FOI""&2CSP5 M392XSLWTZ6$\OSLCT\<)@A566"$J-X9!C"9 HGD"J16+-_))O#<1X4H!_/4I96& 8/4JK!XJ-BFT+H,C3018?PBN(?MC M G.H<>QPM4Z'LDZ7(ER7%=H@;]03B.8[!G<_9Q0![@/O*4-8YFBR2[#$)&%FH+"J7W M"'*KH?QCO+7CTY,LOYEWL56-O+CDO)"0PD"- =;>3W'S_AIPXLZ4+N/1"(?+ M/? 706 -)(S%\.J20$^J"17>;OX"WTRK5YE%S0..:T[&&%I=%BCNY%^CS92Q M4!_^E/E17VE1O&(]BHYJ71HH;N[E*(YAZ7T*]G!$A]WZ_^138TI@*P5$)=M!:P=G[78LX@*[:8?94NRD#9IG'XM(JZ' MY6I%12]G)(<5YRM/"D&^#FHV7*/$=0E@N&->Y-6@2/III_L#5WKSD^<_=$0Q*Q J'@_!+ZK'=O#G8G5N7E;GVI M+.S]R\.-X# -W UP?:64_3AQ+P"J]S>C?P%02P,$% @ P(3Z5I^@&_"Q M @ X@P T !X;"]S='EL97,N>&ULW5=M:]LP$/XK0C]@;F)JXI$8MD!A ML(U"\V%?E5AV!'KQ9+ES^NNGLVPG:75EW8>QS:')W3VZNT=W)YFN6W>2_.'( MN2.]DKK=T*-SS?LD:0]'KEC[SC1<>Z0R5C'G55LG;6,Y*UMP4C)9WMQDB6)" MTV*M.W6G7$L.IM-N0V]H4JPKH\^6E :#7\H4)X],;NB62;&W8EC+E)"G8%Z" MX6"DL<1Y*GQ#%V!IGP*\"!JP'.,HH8T%8Q(RA._]N/P9,&FM5X64,\$E#89B MW3#GN-5W7AD6#\87$!GEW:GQ#&O+3HOE+3T[##\^R=[8DMLYS8).IF(M>05T MK*B/\.M,DP#HG%%>* 6KC68#A\EC%'S8 Y?R 5KXK;J*W5B'_2^FO-CT1=X M=-8T\O1!BEHK'O;^RPF+-9O\R-%8\>2SP:0)P:?EA6;/CO9NF MJ:]PSLM_D/.?K7/--;=,7I+VH_\W5_DMC)/Q]%PZC+ MN.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,J^AV M&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@\;J! M1Y['NXWE 0^L"]CL0/YX'IBIN$^:0ERHY_U=3_ 102P,$% M @ P(3Z5I>*NQS $P( L !?3T\$MP>:4#M.*2VBZD8 M_1!2:5K5N %(MB6/:( M7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1 MH2)8%II%R=.B':5_'FR-9V87YTC'?8Q']>5=2(6NF9MYEJ6R!F_236P@R*2*Y U+2X3[+O,&@EXN1:T/9=1,92L88!.R '<(Y_A^[<#K3P& M]'@!6^AC(,=D",Y1]XVXG\-/O4(VSV'T:$%'J6 M"V&%E+C?Z/F-:#R!+ ]=R_$)'0.M#,,SQ;;!<.AHQ$5V9://8:Q#B'/Z3XRQ MJK"$52Q;#X&'' E<)S"D&IND53 >"CVN*!.L>@PL(:EU&*ADMW,JI]=V<,TB M]RI#FJ,,:&T'X:-:"Q4&L&]R( DNR94;4EWI>::W=Y-[2:AU[D&P]_ :C1W- MCQ^W_ %02P,$% @ P(3Z5B0>FZ*M ^ $ !H !X;"]?+7_OR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J M%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I M2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC M":[?#'!X=/X!4$L#!!0 ( ,"$^E9ED'F2&0$ ,\# 3 6T-O;G1E M;G1?5'EP97-=+GAM;*V334[#,!"%KQ)E6R4N+%B@IAM@"UUP 6-/&JO^DV=: MTMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/$;#HG?78E!U1?!0"50=.8ATB>*ZT(3E) M_)JV(DJUDUL0]\OE@U#!$WBJ*'N4Z]4SM')OJ7CI>1M-\$V9P&)9/(W"S&I* M&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N6%"*JX1<^1UPZGL[0$I&0[&1B5ZE8Y7H MK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC JFQ R!GZ]%T,4TFGC",S[O9_,%F"LC* M30H1.;$$?\>=(\G=560C2&2FKW@ALO7L^T%.6X.^D&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( M ,"$^E9L:'3[?@0 ,L1 8 " @0X( !X;"]W;W)K&PO&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 M " # A/I699!YDAD! #/ P $P @ '8$@ 6T-O;G1E C;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" B% ! end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.biolase.com//20230720/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName - d540125d8k.htm 7 d540125d8k.htm biol-20230720.xsd biol-20230720_lab.xml biol-20230720_pre.xml d540125dex31.htm d540125dex991.htm http://xbrl.sec.gov/dei/2022 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d540125d8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "d540125d8k.htm" ] }, "labelLink": { "local": [ "biol-20230720_lab.xml" ] }, "presentationLink": { "local": [ "biol-20230720_pre.xml" ] }, "schema": { "local": [ "biol-20230720.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "biol", "nsuri": "http://www.biolase.com/20230720", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d540125d8k.htm", "contextRef": "duration_2023-07-20_to_2023-07-20", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.biolase.com//20230720/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d540125d8k.htm", "contextRef": "duration_2023-07-20_to_2023-07-20", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com//20230720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 18 0001193125-23-194657-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-194657-xbrl.zip M4$L#!!0 ( ,"$^E81W.?Z/P, $H+ 1 8FEO;"TR,#(S,#$&C15:C:,L22- 5>I*J/DX:FW, M;2E$]/[X]:NCW^(83L_.+R&&:^<:6S!V>WN;5#.AK):M(PLV*77-((Y[_;^N MOL(_G?4")BB16X2:6X<&/K1"5D6>YGF6I>^2-T.80>[M0<4=%O"6Y?1)\Q%D M>3$Z* Y2./D$'X,9!5>BQB%6-PLCYM<.?B__@( ZU4JAE+B ,Z&X*@67\*6G M_">%HT-U@E2ZMWMBIL>8TU?_T*@!*F;*'(9%N/(Y^)92+N MID8FVLQ9Y0QSBP89*<6DA4:4T0#Z_[@'&*J$E]@5<,;M-(!ZB<]//D!,A99K M;OP%93]4R&,QY&DZ8M00CM*, X@4 MZOL.A!=/B=W0R0/([2@ LL/#0Q:D&Y0JMQ[!TOH!ZX1!FSMGQ+1U>*9-?8HS MWDI"M>J_EDLQ$U@%+6K4&I5;TUG7<-S,T5WR&FW#2WQ*IJF='@N+F&;LWT\7 M7T*G1<<> !":3]2--@ZZ'KS099B-'=GTW^*^"+&_BK,\'F4)&8M /4IZ2P6! MO9A(7]MG$5DUQMY$[+8&]H?8'[9Y?[SMGYV!S7'V\1_Z^+,W>\7_8!W\!"9: M7;Z4S&"G/;\FBHNR6UG='.+++T&GUPI[8*C(1/> M-$+-]/**+GT3%WTG3W &87L5W)1&2]R]XUAC=(/&"5KQ]\/0&;@V.!M'?MW$ M_9[Y)ODTH3W3JSQPL#Y>7LP(@O+BGEZ/=<)Y\(47@Y?36\GERK1OAW%D*>]R M,)Z_.-S&X%/#)8BEY1[*MCWJSP.M)P?O_5R1!OC#U\GYUN=A]3XPQ^^TTO6B MXWBJR]:_0/W_$U5]5,1L<4Z-9>K *@)!#\F$U+_MI;[BV+.LD'ZZB="]6>K_ MZ)==;V%XY*J"SAP,[!VQ32.;]EN+U=_J.)Q++LM6KG*^!"\U=@$WJ[4_\I[9 M=MSRMJ]7/\5LX>6\V MH+)C!=U6HVF1.83!JD'-O??J0>&CFF9,H\50'ZH%B\ M_]W?_AUSD>R\>;>>Q_! A*2$!;RB++926\IO4"&E/9 )@&+@I@S M)DI2]D,^'X#G M%>O'DT_P>Y9N!!])3 ))8![(A CX94GC:.0?^?YP>/1S_\=RF""!UH,H2,@( M?AKXZL^1?PQ#?W3\:O3J"$[?PWDJPV!"YZ0'0^*D-YCQ'HG9'6O>)@^AQ8%0N4*_957+//T0][0 M]XZ'_;6,>F]UPOS9":8DOE)'D'H8"1Z3FL3Z=)J]EZ]/-@NUGJP3PB*2*W_1 MYF&^ZEZ0NTQ5PY=*2A+V9_QA$!&J"?'U@:H:@P79!>MVI"+>T A$6.NIPC_]\Q2#DZG5;)%ZJ6(3?"3XW M5I&GXX:3G^-I;"Q3DZ2.='L3YGVZW>MLL)K M%KGOK49!W,TU3P%I#E!)D+;75DHW[*\-ZG><7I="Z*ZD,@SBOT@@SEETIGXH MLAYD*^.[FFGW&>+UZYPFW5I-K*$W2P)9%M!I0.4!G+C4WR0FRH$MX-LQ'4%M+)SOGG.!=U<'"=A"&+2R,Z'X99:IM*P5!\,;(BB/ M&FZX%<$=@VFVPFL68:!J$,1F-DN!M\&V6+J18^OZ,2;C2Q9RL> BO2YXFZA\ M8[Y4@\QFS*.&%R#V2'4Z-=O9Y-8A[A.UA3SN?+V5$-*,D*<$G1-IW/X*O@S# M]^'F,)KH@L;DPW(^):)9QY3C.FT/@P%N/N\._E,M7,JU.F3R2$!CUVN@UZIH M#% GP?HR4M]CZ!W-[@0=0FVE2*<([[/&+1:[PUTKC$NZ2@7;N7"Y;]6*H0D. M\(/1$J=1I S(_+\KRLBP63L8!3IMA3I+?,]"]Q:H%,7%/]=_61R S@37#&N. M:NA/5KPU])%L6*-?ZP41_;$ZO!83 MOF('@5\.?P[8&^R8H']@O C@X2N.GW>:V,PRE^G5LW]RV+=0-1OP,] MOKGGK.'U\MVXCH"L-,#-YUW -&LAP9F*0ZJ.==VPG7K+D#8IV@W4/P1-$L+& M?#Y?LOQZI+2EM2*X(V3KK?":12[PU@@B$9QG@.T4SA2W6'@9Y:;5N^%\RV,: MTH2RV7LU<0L:Q+8LFR([ KG&!*]:X8)PE1H2OX_R4.@[P]M6R65R&]7MANV- M(+H_B,(B?0.9_BB8N+Z[LQ\*LT4,X#62)(,SF# MWK:),O '.D%%_U+*)1'N#6#0>1YM4&W0W P[ZQ%;HD*[K<;(TK7:'RTYJNV2 M1K8/\T&N'5:S#VT5T][+VTR(#SJ?/VZC;N MJ9;%8]S?.Y\3,5-=\ZO@J^1>#2.+@#7\L&^%1*=W^.IM\;U+W>_QU<@BL9[? M&"L2098)\E1(]_A:M&&XR6?KI?S E3K2OU\H?XAFOV5'/?(_4$L#!!0 ( M ,"$^E8-) Q.X@0 /XM 5 8FEO;"TR,#(S,#&ULU9I= MC^(V%(;O5]K_X*8WK=00"#L[.VB8%668"I7Y$+#]NEF9Y !6'3NRS0#_OG; M+8%D2F:W53Q"!!R_QZ_/XYC8D^N/FX2B9Q"2<-;U6HVFAX!%/"9LT?56TL$R8Y72D= M4C8BG@3(]VW]_O03^F777 >-@0*6@!(L%0CTXXK0N!,VP[#5:GYHO#^4"< F M'HJQ@@ZZ#$+]:H9MU H[[8O.11/U[M$@"\/0E"1PJ.7I5I#%4J'OHN]1IKKE MC &EL$5WA&$6$4S1Q%K^ 0U9U$ ]2M'8R*3V*4$\0]S81Z6$_=DQ;S/C'KU] M@_2?3B2366G7,^G89V,S$[3!Q4+;;;8#*_(.-9L3T;J=25I75U=!=C9?7Y*B MVKJ!5O#;_6@2+2'!OH:@H45'36DWL?I;?6CN(MB=M/4EZ<@LTHA'6>[/Z!8J MK6&^^;::;XK\5NBW6XV-C+T;T^0NJX)3&,,.G\3#7YHQPJM79D,KH-R_# M9J#PAC.>; ,C"6YYM$J *7OLL7C %%';(9MSD60=\5"6T\Y2P+SKF:B^C6;L M?#O6@3Y7":2VJ;XN)$E2"AX*#KJ3"CUTF,IJCW1!3@ ;!2R&V(8Q'?AO.GRS M8[H?N#S*)NQDP"5%CP9^#&(AI,30?3';"+#/ZR^<^U]-%;R:5P)'*9X": MD<*%+:1X!K3K%8B"KVEHU]TQ+(@)S]0#3N!<7\7:O+U#ACT1Y2)C$=FH^N,) MP/PUL*\1I%CH>'ZTU-.=5<\%3PI3M6^-O^27BQA$U],YT5. AU)!N-#5=(F' M5E);XJDQCZDY!W,0 N+1+@FE9C.G>CJ5D-7\RLQZ>JC&9KC>4;PX%]:1J+Z4 MCHQ:/&UG\.R&65_W0& ZU'/4YF?85KNF3L3UQ55BV&)[YPRV_DJ8)-P1&6'Z M.V Q8/&MOF$Z>Y8NU=<77KEGR^_"&7[V-WRJ,WDNL[RFOISR/BV;2^?8/('V M&E>\L$K$]:=U9-AB^^ ,-GLO''&1*_Q*JODC/ MLF\!7SD&^(Y0>%@E,Q#5:![JZH[NT.N>4[OI&*W&LDRSWAQ%AT*J&LC! W3$6FK8(W5F#EW4F_%*$H8L(PW\0 MNK9.W_>BKS\^BBE?LUK6?"*A'7 MEUB)88O-G6V4":)S/SY\67XI07WHON;84W=E#.>K-4,H5B"]G61#'&:(%WBU7=S96 M)A"MC,56.)L21<^^E3S5U9?;J5?+R9W=DZG YCG'R3:9\;-_[HY$]25T9-3B M<6=_Q ZQP29:8K: *L]U%6OK"ZO8KV7FVC[(( &QT&/O)\'7:JGG]Q2SBH\/ ME82H+\$7;5N0_\-6R'5PDIJ1+C"/+>_.F#?S$*XN^0M02P,$% @ P(3Z M5K8W457M%0 XI$ X !D-30P,3(U9#AK+FAT;>T];7/BMM;?.]/_H*&W M=\@,;S;D!9+-G2R;;;G-)IF0/K?/\Z4C;!'<-;8KV2'<7_^<(\G&QB9 F'3 MLC-M,)*EHZ/S?H[$V;^>QBYY9%PXOO>A9-0:)<(\R[<=[^%#*0J'U9,2^=?Y M]]^=C4+H")T]T;&9\Z$T"L.@4Z\_#;A;$\RJ/?B/=6BHFPW3+.F.D:B&TX") MI/>0BD'-YP_UN"73W?,]+QHGG2>324T.CR_8(:_C&W7H5(5>C#M6_-Z3ZWA? M,Z]-FO(EH]UNUV5KW#77,YG ;#2:=6P>4,'B[@/'=S/=\0MHKUG^&$%O-H[- M1@*&<(J @(&-^F]?KOK6B(UIU?%$2#TKF2(*^4* VG5HC3LZPF^9QO$ST.L> MR0M/B_H:T->#M;+?/MY=S;J'Q?UG7>LAIYX8^GQ,0Z 7'.FPVC"KYE%JD"I0 M0V:@F#J6C7-2;1H)+F%RY[FESF$16^TYJM2=C^JJ47==3"=(X25)ZHS:^#=T M0I>=GU1_.:NKC_#=F(64X A5]F?D/'XH=7TO9%Y8O0?B+!%+/7THA>PIK,L1 M21W?J^M!"2%G ]^>GI_9SB,1X=1E'TJV(P*73I$!6.FS.N/[LV#;S MU&?H;^F+, M/!O^"S^[]&'M.8?4%6S99(7(Z,*4G+H]SV9/O[!I'ANY#FN"UH!_)X9AMAIK MPM>-.$=\.,*B[O\RRB\]^Q,-V>_+)TTM8M$H:Z^C6C5,X+[\(NISY,?9D,&4 M%A/PC-*R(Z18@XF(%+0=%-(?2L(9!RYRI_QNQ!$.E)W56&C6GH0=-U-N<1_Y M8&6YO 6)?WY6SZY'KSZS8ODL_(BK1RFE.AK7>H9["38G&&OGA9S=1"'\"&_%+)JHN7PB\\43I89M MP2 DOP RA*VI"N>_K&.<),]#.G;<:>?>&3-!KMF$W/ECZIW*MHF">^"[]FG! M]OQZW;N__$3Z]Q?WE_W%X#3>")S^9??7N]Y][[)/+JX_DS?6K8#0W >-_+OH_]ZY_NK^YKI!/M6Z-F(W#5GL.KKE)EU%FEB"6 M<50A91Z]B#)K#>B6)W)W>7MS=[][F7,;<1&! T!"G_29A32G,&8TB<^)<5BV#W8/ MI3\DX8@A@!%W0@?>OWRR1M1[8.3""@DT&^UF:S&<;[:]:/X@.'@M&6JO-454Y:9UD\(./ MU[3R(*_B]L8F5E6^?*+ U<@*R#L\@9I0043 +'1N;.)XQ D% 3D K,3GI=2> M3A?0Z6L0@W$P.G 9L9CKHI$C(\,@9O YH+8=/^NY]%HMWW5I(%@G_O \CT/(N/IC9YW"9NM'].=#>Z[UD?'0L:BKT:M67-A3 MCV.N,4X,<_$K\P/"_S3L/.X2T =6'7!&OV*0&%SZ#GWT@436PEQI;EZ2(B>2 MH:>.I"0RMQ8@"H P+6+FV?<9XU:)G)YG^1R4G=13_1 T4->/O)!/N[[]*FV& ML@Z#$R$+N/^(TZ(Z^\1<.@'-MM R7I4,8J+/]=\!#C\[+H.V ]6.21K5Y MU#PY?&<(>;%+I3!V3Y]Z.@IF212]$'TGQ]5&JV6V6KEH:(*_&1JWP<4G;\/$ M98V<)VI#MP-N"DCA:XDV;E@V^;@,I=?SQV!"8R";(/N?9K MWSK(O;L^N1P'KC]E7"$]2\.Y-4B"@_^A1GZ%X[,1FVT)0U[8-F="Z#]78#49 M:S.C>=QHF>3>GWB,R%P-(Y^X\YB3]97%/M4B8,RU@>E'()0(@+3$7=J!^;S: MZKOP\88C-M=>^Q7]RLAG'T8)7XI[*6]N^"VH;D=F;C=M"'0!)]#)<^CJF&WI5 0?$.P%U"7MB5A0"(\'7(&N8 M."!E6#?!A3\3^WDST3+S6O_YPXEI')\*$+\N"T8^" )/*O8**B#@/5' M8;M UR[>:23^"^CWHKTMMUOM@SQ5O=ADN?)!4=SB:EYHI32/C*IA-@KHK2@< MO(LMO*Y?[)[X06(!7G18@4L1 H]4L010T)"HD")H>91)Q*4BCM3M@PO;":DO M(RZ0XR-F?97!7QJ ? >IA8;JP'\B ^;Z$]PU;,2]7-'T=N2#WF1\*=$@&<)X93.8-^P1\ OI0YIH/2J?!4!., 17G3 MN&WHNP DOH>ZR4%S5'06TM+1B\,Q&PVW)#&66=PE'^"9"P"MYO?,NS)J@M:/ MIX7F\B)Y^1_NA+!E:.%'GK:-Q:LMB('ONP,*VQ4"<2&6V\>MUFE>I"[S'23L MJ>TEV1TEKY:W<^4-I7.-#T! &B$D2&5V[B(@DI9YJ"ET+I>"*92R<4RZG^^( MV6S4H..!XNYGG(P]V:Y)MGV0PA8@W'OX B(,Y)C[-Z;9&3)@:(6-/,$NE>=& MBX+A$XOT&6UGDH,Q92\=S6PU:FK$@Y3EM&>"33+!+6E0--QA8"3?=X/$@5?5DC8KE4B(1QMYQV>BD2=XTQ3I%[ M5=*K/QU#O[(XV"/M^9BJ+H^25,9B'1/G:X$KX.N9S,ZJCF^VUF2A\ZSTT-0P M!Y*]UHZ1H\'D>Z0?^M;7"@DH)X_4C1CY1P/VVR !GK09%1:.["A9O @3FE<4 ME[SHR-ZWLL3M94G728K&E!5;:2\Y"9DSH)$=XTSD/9A"UU38]$]%?>0+Y5]9 M2*ZN92[.[@@"QC/8[SCI WG@_B0.I$E$5^FP(W))XTXNC30" M"F8N^%5 P9XOO:Q(,-D+4*2357AHWI%Y*'7($E$BIW*G./?$@9F1&SP #UHX M>W0$O =\03T+PZW4LK 2$SOC\7F;4/"4B6_5-1#/9Z^;V^^]R$;R/-W>?+N^JW9NK MJXO;_F4G_O!M1_ ,HS"$1^1'(*1\;"I?_]<+V5A1!]!:LU90K)@>;5<1M^<\ M$[7,.+M%OOCVK'81XVCXDJP]BFTN\C.,P+BHD74LCJ--B.I[?R9/L=7"D\L-<%(Y3X** MVORIH+F#M*\*VN]9OG%Z^*Y9/KG212"?7R!X+I.8QE? MQ4)%LW':C:UC>#).#RJJAND1V(VBI17X NVP4,Z6ZBM+'.4Y-V@&)U+:: ! M!J#T/'W=]XOJ&\]'AA&7[A/%_8E%T/Q$=TP6S]JDBW0U5!;J_-95T*N2PT#' MS!*?>6FV;J *-AR"&0D+YUH$RM7 ,E$$:G-R'C1+!6U$<=!&[5D2N9G'?!+N M2:%?SH^PK5"NN:S#@(43# MOW.3C"+/!DV60 &"$%:.[H ?H:*S(RNF!##"1CX'1K%U&:TD,L2EI/)2-NG19BFN4KA]'WW0?#C2)]"M5N@#U:88 #T15^__IO;$'[X$/>G%B<@: M:2BI6T'5FA(/1VGQH%>+A8&X'D^Q!TI!)'?9XQG>R%!K(C\3SI7NFPX=YKWTRY%3ZITA-BG@GCNN"*05&CHB4#04& ME:>\V!EJ"^"NP281UV$18B0W;D7N>02X40+GGD<9LXL/6 /GDS%G#P]DD5 M \&O%W&&%&P&5OMG!%N19R$W1XI\%3V:27G0!3+H(_>V4.(K=$M)^.1@C1Y0 MEM%H*3D "W21E_2K@/"YCK7BGC5RBV8/USM&[3^ @Y3A&//LF-HL%J S>#.0 M(5M+!R(*X#OVQ+B%FRGC7YZ^OG2129%>.#I]X(2B\+05BTTDCX5"LO&$(6.* MN/CQ+3HT(() M#=N:%DCD7K+?A'1_[?=NXQTH''&8L0B*Z ]@.70:D=K(__C*;OP6HG"9 M,S+2AI66JXA<%2G$QT=?.<#*8HG]9O"0<8EAJ$_NI'WC!2[UG-.B+.K4:R.& MQD%10&#[PFL)6=[&T0)#4V2<9H&E@=#.+ /PI7"BG2VEP&Q_@51QBIA.5_0].\\(S*T7([Y:H)XDM8AM MR_S76,A"8C/E+K&6I>_F1^U_1/4?0KWVOBL:"6'39S4S< M;+24\'1 K:\/W(\\NZISUY;%0 '-FWW/&'MQPAHT^,E)NW+8:E6.CH\V4.JV M\E;,0V*T*HUCLW+2-"O'QZU=0M(\:E;:#;-RV&SO$@RIJ\W3-#F]1:G9JI96 M4F05&UGW,XL*H[WV'W[$/6E"Q1'97% 7F,+YLRLK?CYN6Q9QOR/DPPSJ[DFXQH*'1;>ZS"1&!/:^]@; MA[LV[?;&X=XX?)=KV1N'[]@X;())9E1:QR>55K.Q4^/0J)P<-BO&X6&E:>S4 M.&PUC,I1ZZABM@[_AL8A6@D%90LC6:*7Q)QT4;8V 8ML/QF25#8VJD]3 MZJ)HG:"6*?-4:GZ6*4!QBIZ83#7+:_U5JMJ/!'$=DT3Z\!8@=H!L/OJF(./ZJI0)E48I= MIO5'5&=Y;"9D&;MVT#&MD@0#W*GPV[K7I!S$8";PMNDM%AO^9;7>>R^RB%IIV8)^5M%TM>N?:+6'@5E_;UCNW: M$F %7)+X-Z(EO5>1OE]UO0C^;DJF;B[FSZQPR$=T4KR0OP$DOKD86PHPF&H& ME8D,"W1EOO$OXN1%=N$>IHFA63.V147JY@]*U$\DVX>MAF$>VNRI:=1&X1AO MXT)?9)1-X*QT?B=W?@D$+UV(ZK_+MJ+A]=9[V6[KS;S-F(;Y\V6VW-2\_;O? M.71?&VL'2=?:N*X/WY);6"'L!F@ZJ@[+?,*3"O+W9,IL#)X#GH;#$C>=C>UY M>&4 ^>WCW16Q]<\W'A2&,-]IZ*^Y#_T5A?YV^G,O_=Y/UQ?WO]Y=]K?NG*=_ M+#85'5!NQ6IWW52*+CNQ0<@1BT9X04G:"=8'G&"U3!;F8EQHP$;4'<9EG_*6 M3=T!W>/(@W?D<+,BT[^FDU'H5F2INGD<>P7K.!K/WAMIM-<:\IF1#C<.6_,H MXP1M*?^X0IIQ$S>JK8[.E4=.='IS4<3B&2]F[J=B7VY](,L]9W[(]KS]L:V^ MN[-KU(]%=PHLO&^3?-8GF6GG3>=;[^:\)3I'7W_ M3EGK.:?LK#[P[2E\,PK'[OG_ U!+ P04 " # A/I6$F?3;BX( "+)0 M$ &0U-# Q,C5D97@S,2YH=&WM6NMOVDH6_X[$_W#D;J_:%2% 'KZWP0PP6V-;,T-(]J_?,S.VL4V2AB:Y[4I%(L7S.,_?>8RGK;[[ M<=!N]>U.KUTNM5S''=AM^U\'1]5ZZ] \X?!A/ ^MBU'O*UQ<=D>#T?C<^M)W M7-N"B?MU8)];/@OHP9*RQ5(VAR%?$=]J0[F$^[LTD)2W6SWG<[)XPV9RV7Q7 M/6&!!<1GBP )T+FT-)NK9-F*\ 4+#F08-6N1/(/X>1I*&:[,T#P,Y(%@_Z7- M^O9Y3E;,OVVZ;$4%#.D&QN&*(*?.P+DV?;-D4R8!=8;6 MX:=VZQ"'#Z^4XG?)46\\HR">MHR69&)_MH=N'SH?[6$/ORXD@KR\/3)BN"/E M\)_ >&Q/W(YK]Z!KCUWG@]/%!QA] &?8'8VO1N..ZXR&\!WGO)!L*,9/LC^A,B($7A7>R"6%/U[5C_\\P\CI MACP*.9$L#%3@J/%W9V\K0,#;SD#(%R1 ;C,@P0SH#1.2!0M8HT!<#TUOX9IQ MN:80SD$QN*0!Y<0OES(,8$ VR?Q$$JD7]ZA/-H33"BPIITC'HURR.4,5B$"] M?#_WJBL*0)AU#=\Y\_+5A&W MBE,*R3OQ68B;>_A#CGTFHJH:P=HK^&>L_B@0_L;THS'=^ 4QW4'?>ZBCXS@) M%5S45H:2^!"L5U,L!*BE6&*HZ+@5,O2^H46(+(:P6N3[L"375$^1M5R& MG*&:,D3#""PB:)[1T"Z7^I^&O3'V$[9SV7>_JC'XZ P&JHMX4W]7K]1J-?5] MF^&[63)O&7-7ZPLD,MMK=VW_1ZU:J]4A(ARNB8^B1*B8GH[%GE*LC*N54D/S M4'Y+V>8%_$'ZY5+$Z9QRCD#0/*K%ZO?B'<.G"/53OL%\J0J]KOKS.?4DN\;" M+D0A&]K)'"A2F;0'T9J+-<$$C[[-] 5P=UM0+NWF73V#@)A09(UY>ULSD.3C MHFVWC%2 DMA?,4!,-GU3S[LKYVJ*90.]I2%J C9<2^0?S)2-0HXA[>M6J AX M#&>)V4^LL= 84FRUHC.&POJW6.]8R,NEV$!Y4QI05%2,H&#3K6:M:ABR MQ]_X[!DUC<\06S)1&=6(8G++T,=N39=83L-Y)4;R%(]\1ADO#*[1BCK]H#!A M@#6O_M;8Q2"T:)!B2<3M0I5.-3>)?"9W"N"^![(GH7@8PIP;VR#B8J>F41R[ M$7V#B@?4F##M#.Y0IHJH I_1]=:$.GTM%IPN8MPIVCL\RZ50[=@P8;B2J4^3 M>$B\@GLY1*#D)Q%RUWPLTCFETU"\T"3=R>5ZX#J1(Q/H^)XWH M5%)5?*1O&.I<35+--,DX:^6D6IFJ((AOFC'%-T9BQBI,'8XP< 6:VZAF<@M- M@R>OG-)-A,@6_XTT&4^;D,R1SEU!$P?"E B6]I"84Z^)R6:(LV]4JKCS:#J? MMX0I6E(3,_-*IRIT-$NQ5B4&!RIW2:N4PAQ.=#W32W=-C]L85YTN8(I(3!ES MBFNJEC#T*,6V&'>C^2'AY4#4?HU.O-D_<055?5"MA$8-4*=.FN)+5[%F,L/H D20T/"(]_9?.( M3/72EP+_5)^=SC=#L?'#$"\BKXC,+!*S"'[6T&BKRR$#\W;\(X7QT1&&@+9^ M.I, U.BVE3%9^-P$&LFX]O]6UL0(]P0D[&F$@G Z_++B%*1.W7GO"AB.OHP[ MS]7 W7O=D=]65ZFN@%]E,I30^7@)DW'WW%J<'-?JC1.V6M2K_XD6:KU[;@U& MER.KG4GM/ZIWSEEIN*KKQ.A1*ICDMC75N\=:XKGC_J!^ '&X*D5ZSF?4*KY# MU2!4^D>F,N2S$%WM"*.&,DB=4I5JF\3?D%NA\OQAI*S51U0[_T;5CJR$KK[C M;;YZKS^%C! +W+6'KCW^6VYYGW26;UVTG2%JX [MR02^].VQ/?J@+M,J.V]; MEEAB/+(6ZE3ZX)T#'L_4VS:!.B5K&Z=89V9$%Y>_L,>N0*/6.'K@-+5W M>V MS=]A[YW3CW]62O_SB0GY_<]+R(#60-,.57SLW,N:6]E$K+Q(&=H9TGW]/AD5 M/;Z7^SNLF"M*>UNQV(0_<\5I#['-;MYAH_V\MM_%CWHA MV(3NDM$YV#?46ZN6OEP:S3&]%CVT+>"F_OU?EO'&=\HX)HY1[RL.ZO^$]3]0 M2P,$% @ P(3Z5O="X#4P[*3=IW,;B89FR!P<9_G/IC3-^.W@\[IF][91:=:.1WWQX-> MI_?/QO%QLWVZYQZQONS.X&;ZN?7S3'_=J;#3^-.B]KD4R M$8VYD+-Y=G*M=,RC6H=5*SC?%4DF=.?THO^AV+R0838_.6H>RJ3&>"1G"0B( M:5:SU[PKML53*6 ML3#L6BS84,4<-YT-^E?7KVN:F*QU3L\[O<]S.9$9(XG9Z=YYYW3O76>-@37J M^Z"^Q<\]=FJ=GY*)25\1%0C^D!SWSQ62H,%GU#A>?]F M<#;JL;/KZYOWU]W>"'Q?WER/2U//928:)N6!.$G40O,4Q[ZTH=VXO!DVVJW6 MZ1YM[?@?;-C[T!OBLM'XIOLK&[T;],>[S/8=Q.[>O'U[<^T9^=@?#*J5\]Y5 M_YJ-AV<7_>LK1B^)O\;9Q2_O1^/>!3L_&_5'M/[+^\$GYRC[1W6VW]H_^!Y" M$-<#?BO8I=+"9'761>!-FW7V2QXM[?W$@OWAF7OAF?OIA_9AZ]7:%O?>6[Y> MK?23H+E]^MGUV>CB[!\GC+;]?._P,Q!]_K*@00]'KYC2+)L+YEYU59SR9.E> M_5QGG,TB->$1BP0/A68R82'L00O<"&WJ+%,A7S*>)"I/ A&"%L\8HGLNHA#' M32H"B>VQ$)E,9DQ-\=(PDZG@=JXBT#1,)58=7@$MKX#%7&AA65MCZL4K4ZUL M')YI#O\([<9SQ75(5UQ(+8),X34MA]($&M?CGDPQ,9WB'5C3X@X$A.,%C$;@ M&F?OW\@"%<Y:#')N(;"%$PIXB]C+5V-\*/)Z$GG2U\E\31UPWM^B/ MYDIGT1(.'$5J0=8AV;M]" M1A%L ZL)SXB\$V2W=OOD\)BES;C)>MP 51)& ;OE@"^= ]:M_K_D#?XN8 3+ M- ^MBR%&&N*!"*I4)#X8Z!$8YDG T;8V-G?O;+)W6J7P=BS!M9U58@"9*0P(-8:" M"&[RO>)U#32WG:!:D<;D?!()EJ=8+"*#H#50"2F*6+E/9%TKXO=<9@#2!0+- M6-?#;X1MP%@.-@78Y [/(',D WM?>56J92":;&Q!LY I42R8\V16"I8I@NZ5 M>#S/@ %PE/!+5L'5!CX*+\CFE 5 K5H9(J5Q\NZN@&JGX"D31 &I26FHFV=> M[K4HLM)PZ#X48?-[^#8T S)+EN9@R8B"G;_L\C[_>)^7U@LU)QM\%=E4Z(;5 M=4&V@ UKP:])0.3U!-AD#)M,X6- ZESEAD729!Z#B,PU-R'_'45'*LGP;RW0 MP (@ACW8H>$FB9B"BO6=W0:CP+AT9.4:N\[_61*791U6_R& M\M(7VJ/UDN-T[_TC=>.+I^#ES"6*5?;*;)YRSK$#>^L%M&Q65A8(D+ %D5 ) M$ %76'4^#+\D-EU L-LJ8(&JN28;(J>B#"CKM@=(;-S*R<$3PP.K5(L7!+S8 M!" !Z93J! ]/XK.'*T)>*BK\[>3HB-VL44IN8Z_ =F(B1S9W@HTUL'V%-M?- MLZ:K82P?4_@3GQ$#1'23?1_9=2< I_K%;/)E3[K"(. )02S%'G8" ^&XSXY: MK9^_# &'SU\T#MO/VT4]]LU3?.$;5JY$$6J97"#3.JMP9.TBHU(HXY<\REPB M?L#?X N<,*"^I7RGN=E,BQGE N#4VBV%.4E]-K=!HU/7?L3D E"G@6LQ"P[D M\,CHX#\ADTTSH?]<2!3%%OXE@!=QQV54XJSQ"%FM[$2\)CNS%SHGY)'8*6>* MQH=J78Y-+B:('>V"Q!U=!6,!ABA7J'O@JS"T%0=R*]X$0B#Y8S?D"U<&( Z* MG6OJE-08(P43$_ SNB]?L;)0.71ID7I!V0G:A?/*+$+>I0'3MW4Y]+LL1L\+ M)E>0ZK/23OQ*"?7I'44H!-HJE:C*(V^ Q&A.3.$WNQK'^RWG9LM8]\KR$>9>G)WMYBL6A.I*(. MN0EDH73AMI#C>QV,>EW#>A=79\."4+TD0^>-")HS=4=G?>:C05/ZM<,MMFZN MH\TAV;>?]14CFW;!.?G;1?\#LJ:?2T(8^Q<2F6P9B4T/%/$]5F@I!?PV)EKP MV\9$P '$"8\6?&EJA* I#?_>#-FH_R\(=E KZ-JYZ>3E!^%J]N+J6]%,(4H[R-@ MTQT5:K["<_D":R)2*0(+A_,I\"FWM:+K:XW+EP8-C'%3(V:6Z(EC4TR34#?J MI=UD;Y$)BKW[X8^N,C/5"@_O>.+[R]1BH:L;=Q-RI0/0Q_9Z]&8N>)3- \)> M$)TB]"V8FEU7(E6(C'H'QW;!!/@N^ANQU8#NOWA!UPD[DJ+K]@_]1."CB/R=1!-*T(&WT'9DA:E6 B0N_VQR5,22A!+: BOI MPM92$43!790\<>_4SC=L,K*U'"7+^S+*)%%WW&;34KB"C2#/"#X;(J3^L6!Z M26F5K ]L]>=L.@7_H8BPH%,EU4D_Z(3;&A\T[<%.76(H$R,<0)7%T'V2+Q M&5)H:X.BVZ;+3=-%Q"4EYO;Q\5&9,RY0[5)3[=X?M&TJVB^K^@%:]4OSXR28GV]?Q\#=.$%X&O=-+8O*8WJ[K@SV"1$]72.0I MZ<3YSE8]\9$J M(AD^^BW)R.WN_XCO3R\,=7[(YF%)"F80'\!!PB*:).14[$ MH4Y]C53OO7D/NA?7A0TB-NG75+;*JSJ<1J >4JH0]X%%$^ZV]5 M#75V"4-,E+I=VS/U2[1ISQ]PF\? 0KZU=[,K:QOA=N[W?T$S=A,0;R.16A/UD[<[(+LG$4O!Y8IW/;S_1].K]\^;; MZ0U_W:6LAI[,03T0SB0!.V4,S4-!L4N-^.;'(1K /5[C/\W Y+S3Y24JC\K6 M?HCF3UMD1?#2/+,Q@+_2<[G'?)^[L7T#7YSB1K9S17J*I-P<\W,J9G<7 MV+/%DB_K:GFJE M.&>GE6)SI_A,@Z#-M0D*"J2RS44H4%*)D&T3,)DMPC9787RDL"VZ**E)P5L[ M%55IZ!NWEJ-MF8P0Y5%;V$HX']=,N*1!:=&NWW%TJC9+5BN^64UH*H(:R?AF MGF;&<#%#'PIUHG]Y(5W/9V:QMF$MW(#"8<&I;[2>'(->:0L^J; H7 M=OIT][N!BT'Z3E?/KOS9H*G+N-VJ%OA$1O1Q@B;=*)\1?8R*_Y4IPG*,7 XM M:&B\H\U?55W%()A^IX-?,[JF$22WLT>2/W#@@]MIID45=(3<2$503D@925L< M.WI&/!KQ;B*@Q32B<>1VL>25>T^G)D4O2EE\2>'F;.KK-_L@2]QI$C3D/"IK M8L0F"^64AAW%4(.^Q)+RON;V4!3MA#4_7_NF0_V7TJ;P&?]8V'MC@F]G]_1- MQ"(2NP=(?K)O2T43:#E98:"+A2'.52N7[@H?$T8$#TQ,>)(X%=!0!950).PX MY)*0\\N?8UJ-7XMYJ3MJNQX[2Q'0D;0,DPB]8EK;57$L;40V:5&D=J#KOV7 M9:FO6ZPFYZ$" ?(D6T5G]+\VR,MI1@V5R_48N'-?]ZH55YG:?0^[U[>O>)") MJ4Z>YMJBR%J-7 [6_*":TN[)8U7[DR3>WH'S]9G_MV0K M3KTZ_B[N@AG9@@IR5R?NN1_9K=70QH;_VUGC_N.S1OC]S<4G+-K_?OD?4$L! M A0#% @ P(3Z5A''-D4$L! A0#% @ P(3Z5D=?G;2U!@ ITD !4 M ( !;@, &)I;VPM,C R,S W,C!?;&%B+GAM;%!+ 0(4 Q0 M ( ,"$^E8-) Q.X@0 /XM 5 " 58* !B:6]L+3(P M,C,P-S(P7W!R92YX;6Q02P$"% ,4 " # A/I6MC=15>T5 #BD0 #@ M @ %K#P 9#4T,#$R-60X:RYH=&U02P$"% ,4 " # A/I6 M$F?3;BX( "+)0 $ @ &$)0 9#4T,#$R-61E>#,Q+FAT M;5!+ 0(4 Q0 ( ,"$^E;W7,J/6 T (4I 1 " > M I !D-30P,3(U9&5X.3DQ+FAT;5!+!08 !@ & 'X! !G.P ! end